Status:
RECRUITING
Alveolar and Serum sRAGE in Severe Asthma in Children
Lead Sponsor:
University Hospital, Clermont-Ferrand
Conditions:
Asthma in Children
Eligibility:
All Genders
1-16 years
Brief Summary
sRAGE is a recognized marker of alveolar injury in acute respiratory distress syndrome (ARDS). More recently, it seems to be an interesting marker in asthma. It is the soluble form of the pro-inflamma...
Eligibility Criteria
Inclusion
- severe asthma
- Weight greater than or equal to 5 kg
Exclusion
- Current respiratory infection
- Bronchopulmonary dysplasia or prematurity \< 34 weeks
- Diffuse infiltrative pneumonia
- Cystic fibrosis, primary ciliary dyskinesia
- Known immune deficiencies;
- Congenital heart disease;
- Cardiomyopathy;
- Ongoing pericarditis, myopericarditis, endocarditis;
- Chronic valvular pathology;
- Known autoimmune disease;
- Neuromuscular pathology;
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT05364996
Start Date
June 1 2022
End Date
June 1 2024
Last Update
April 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Clermont-Ferrand
Clermont-Ferrand, France, 63000